RT Journal Article SR Electronic T1 Response to Comment on “Epigenetic activation of the drug transporter OCT2 sensitizes renal cell carcinoma to oxaliplatin” JF Science Translational Medicine FD American Association for the Advancement of Science SP eaam6298 DO 10.1126/scitranslmed.aam6298 VO 9 IS 391 A1 Zheng, Xiaoli A1 Liu, Yanqing A1 Yu, Qinqin A1 Wang, Hua A1 Tan, Fuqing A1 Zhu, Qianying A1 Yuan, Lingmin A1 Jiang, Huidi A1 Zeng, Su A1 Yu, Lushan YR 2017 UL http://stm.sciencemag.org/content/9/391/eaam6298.abstract AB OCT2 plays a key role in synergy between decitabine and oxaliplatin in renal cell carcinoma cell lines.